Ultragenyx agrees to sell rare‑pediatric priority review voucher for $210 million

Ultragenyx Pharmaceutical entered a definitive agreement to transfer a Rare Pediatric Disease Priority Review Voucher to an undisclosed buyer for $210 million. The voucher was earned after the FDA granted accelerated approval of the gene therapy Genglycos (GENGLYCOS) for glycogen storage disease type Ia on August 19, 2026. The transaction is subject to customary closing conditions, including the Hart‑Scott‑Rodino waiting period, and is being advised by Jefferies and Gibson Dunn.

The company says the cash will be used to fund its rare‑disease pipeline and support its path to profitability. Shares rose about 3 % after the announcement, reflecting investor interest in the non‑dilutive capital.

  • 1Ultragenyx will receive $210 million for the voucher.
  • 2The voucher originated from FDA accelerated approval of Genglycos on August 19, 2026.
  • 3Closing of the sale requires satisfaction of the Hart‑Scott‑Rodino waiting period.
  • 4Jefferies is the exclusive financial advisor and Gibson Dunn is legal counsel.
  • 5Twenty percent of the proceeds are earmarked for the National Institutes of Health.

Sources